MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Charles River Laboratories International Retained Earnings 2011-2026 | CRL
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.39 B | 1.81 B | 1.89 B | 1.43 B | 981 M | 625 M | 280 M | 42.1 M | 289 M | 165 M | 10.5 M | -139 M | -266 M | -368 M | -466 M | -575 M | -238 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | -575 M | 404 M |
Quarterly Retained Earnings Charles River Laboratories International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.94 B | 1.89 B | 1.84 B | 1.81 B | 2.12 B | 2.05 B | - | 1.89 B | 1.72 B | 1.63 B | 1.54 B | 1.43 B | 1.28 B | - | 1.07 B | 981 M | 879 M | 775 M | 687 M | 625 M | 625 M | 625 M | 625 M | 280 M | 280 M | 280 M | 280 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 289 M | 289 M | 289 M | 289 M | 165 M | 165 M | 165 M | 165 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | -139 M | -139 M | -139 M | -139 M | -265 M | -265 M | -265 M | -265 M | -368 M | -368 M | -368 M | -368 M | -466 M | -466 M | -466 M | -466 M | -232 M | -207 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.12 B | -466 M | 453 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Castle Biosciences
CSTL
|
-224 M | $ 20.15 | -1.9 % | $ 584 M |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 118.95 | 0.8 % | $ 14.9 B | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 17.11 | -1.55 % | $ 517 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 116.78 | 0.18 % | $ 9.63 B |  Irlanda |
 |
Agilent Technologies
A
|
348 M | $ 114.96 | 0.15 % | $ 34.9 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 138.23 | -3.02 % | $ 6.46 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 5.07 | 36.66 % | $ 6.74 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.63 | 0.28 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 144.41 | -0.29 % | $ 23 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.82 | 1.11 % | $ 8.05 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 103.0 | 9.03 % | $ 6.95 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 432.8 | 0.63 % | $ 12.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 103.09 | 1.16 % | $ 22.7 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-166 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
-631 M | $ 8.47 | 2.67 % | $ 756 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.23 | 1.32 % | $ 1.18 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 19.08 | 0.21 % | $ 427 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 203.19 | -0.25 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 3.82 | -2.3 % | $ 354 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 6.34 | 2.92 % | $ 265 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 60.57 | 2.95 % | $ 3.62 B | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.49 | 2.05 % | $ 5.72 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 259.93 | 1.63 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 448.28 | -0.24 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.6 | -3.7 % | $ 216 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 8.9 | 0.45 % | $ 1.93 B | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 342.37 | 0.4 % | $ 20.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 195.21 | 0.72 % | $ 21.7 B | USA |